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ABSTRACT 
Myosin VI is involved in many cellular 
processes ranging from endocytosis to 
transcription. This multifunctional 
potential is achieved through 
alternative isoform splicing and through 
interactions of myosin VI with a diverse 
network of binding partners. However, 
the interplay between these two modes 
of regulation remains unexplored. To 
this end, we compared two different 
binding partners and their interactions 
with myosin VI by exploring the kinetic 
properties of recombinant proteins and 
their distribution in mammalian cells 
using fluorescence imaging. We found 
that selectivity for these binding 
partners is achieved through a high-
affinity and a low-affinity motif within 
myosin VI. These two motifs allowed 
competition among partners for myosin 
VI. Exploring how this competition 
affects the activity of nuclear myosin VI, 
we demonstrate the impact of a 
concentration-driven interaction with 
the low-affinity binding partner DAB2, 
finding that this interaction blocks the 
ability of nuclear myosin VI to bind DNA 
and its transcriptional activity in vitro. 
We conclude that loss of DAB2, a tumor 
suppressor, may enhance myosin VI±
mediated transcription. We propose 
that the frequent loss of specific myosin 
VI partner proteins during the onset of 
cancer leads to a higher level of nuclear 
myosin VI activity.  
 
INTRODUCTION 
Myosin VI (MVI) is an actin-based 
molecular motor which performs 
numerous vital roles in key cellular 
processes such as cell migration, 
endocytosis, exocytosis and 
transcription (1-3). Defects in MVI lead 
to various diseases including 
hypertrophic cardiomyopathy, 
deafness and cancer (4-7).  
MVI consists of the highly 
conserved actin-binding motor domain, 
a neck region and a C-terminal globular 
cargo binding domain (CBD) (Figure 
1a). We have recently shown that MVI 
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can adopt a back-folded conformation, 
in which the CBD is brought in close 
proximity to the motor domain (Figure 
1b) (3). Moreover, two regions within 
the tail (MVITAIL, aa 814-1253) can be 
alternatively spliced, resulting in a 31 
residue insertion (large-insert, LI) 
adjacent to the CBD, and/or an 9 
residue insertion in the middle of the 
CBD (small-insert, SI) (8). This leads to 
several splice isoforms, namely the 
non-insert (NI), SI, LI and LI+SI, each 
with distinct intracellular distributions 
and functions (8,9). For example, the NI 
isoform is able to enter the nucleus, 
whereas the LI is confined to the cell 
periphery (3).  
The intracellular localisation and 
function of MVI is also regulated 
through its interaction with a broad 
range of binding partners,  such as 
disabled-2 (DAB2), the GAIP-
interacting protein C-terminus (GIPC) 
and the nuclear dot protein 52 
(NDP52). These partners specifically 
bind to one of two established motifs 
within the CBD of MVI, namely the RRL 
and WWY (10-12).  
NDP52, also known as 
CALCOCO2, is an RRL binding partner 
of MVI. It was initially identified in the 
nucleus (13), but it was later found to be 
mostly cytoplasmic (14), with roles in 
cell adhesion and autophagy (10,15). 
NDP52 has been shown to release the 
back-folded conformation of MVI, 
allowing MVI to dimerize and to interact 
with DNA, both of which enable 
coupling of MVI to RNA Polymerase II. 
Moreover, NDP52 has been shown to 
have a role in regulating transcription 
(3), possibly as a co-activator, similarly 
to its highly conserved family member 
CoCoA (16).  
DAB2, also known as 
Differentially expressed in Ovarian 
Carcinoma (DOC-2), links MVI to 
clathrin-coated vesicles at the early 
stages of endocytosis (12), through 
interaction with the WWY motif. DAB2 
is down-regulated in majority of breast 
and ovarian cancers. Moreover, 
depletion and re-expression of DAB2 
can trigger tumorigenesis or suppress 
growth, respectively (17). Therefore, 
DAB2 is considered as a tumour 
suppressor. 
The selectivity of MVI for its 
binding partners is, in part, regulated by 
isoform splicing. The LI encodes an 
alpha helix which sits upon, and 
therefore blocks, the RRL motif (18). 
This prevents partners, such as 
NDP52, interacting with the protein, 
and therefore the binding partner 
interactions of this isoform are driven by 
the WWY motif. In contrast, in the NI 
isoform, both the RRL and WWY motifs 
are available for binding. In this case, 
binding partner selectivity would be an 
important regulatory mechanism. In the 
light of our recent work on the 
regulation of the NI isoform by NDP52 
(3) and with the aim to unravel such a 
regulatory the mechanism, we have 
established how competition between 
the two binding sites is achieved and 
how this can impact upon the role of 
nuclear MVI in gene expression. 
 
RESULTS 
 
Interactions between binding 
partners and myosin VI 
In order to establish how the selectivity 
of MVI for its binding partners is 
regulated, we compared its interactions 
with two binding partners, namely 
NDP52 and DAB2, as representatives 
of RRL and WWY binding proteins, 
respectively. Given our recent work on 
the interaction of the NI isoform with 
NDP52 (3), here we focus on the 
interaction with DAB2. 
Before investigating the effect of DAB2 
upon MVI, we first assessed their 
interaction. Recombinant full length 
DAB2 was highly unstable and unable 
to yield sufficient amounts of protein for 
biochemical characterisation. 
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Therefore, we used the stable C-
Terminal region of the protein (residues 
649-770), which contains the MVI 
binding site (12). This truncation of 
DAB2 will be referred to as tDAB2 
throughout the manuscript, unless 
stated. To characterise the interaction 
between MVI and tDAB2, we performed 
an in vitro FRET assay by titrating 
Alexa555-MVITAIL(NI) or Alexa555-
MVITAIL(LI) against FITC-DAB2. As 
demonstrated by the binding curves in 
Figures 1c and 1d, tDAB2 displayed 
relatively weak binding to the MVITAIL(NI) 
(Kd 11.6 PM). Binding was noticeably 
enhanced for the MVITAIL(LI) (Kd 3.5 PM), 
suggesting that the LI stabilises the 
interaction with tDAB2. For 
comparison, measurements were also 
performed with NDP52. Consistent with 
the previous results (3), MVITAIL(NI) 
bound to NDP52 with a low micromolar 
affinity (Kd 2.1 PM). In contrast, binding 
to the MVITAIL(LI) was over 8-fold weaker 
(Kd 17.3 PM), indicating that NDP52 
selectively interacts with MVITAIL(NI), 
rather than the MVITAIL(LI). Based on this 
data, the differential affinity between 
the WWY and RRL sites suggests that 
the NI isoform would selectively bind 
RRL binding partners over its WWY 
competitors. In contrast, the LI isoform 
shows preferential binding to the WWY 
partners because the LI helix (i) masks 
the higher affinity RRL motif (18), 
thereby impeding NDP52 binding, and 
(ii) may provide additional interaction 
sites to increase the DAB2 affinity. 
To further explore these interactions 
with full length proteins, we assessed 
their association within cells. In HeLa 
cells, which only express the NI isoform 
(19), endogenous MVI shows little co-
localisation with endogenous DAB2, if 
any (Figure 2a). In contrast, transiently 
expressed GFP-LI showed significant 
co-localisation with endogenous DAB2, 
as highlighted by the 10-fold increase in 
PHDUVRQ¶V FRHIILFLHQW (Figure 2b and 
2d). Consistent with the titration 
measurements, these observations 
support that the selectivity of MVI for its 
partners differs depending on the 
isoform.  
Our biochemical data suggested that 
the association of MVI with its partners 
is a concentration dependent process. 
To address this in the cellular 
environment, we artificially increased 
the intracellular levels of the NI isoform 
by transient overexpression of GFP-NI-
MVI and assessed its colocalization 
with endogenous DAB2. Consistent 
with our titration data, increase in the NI 
intracellular levels shifted the extent of 
colocalization between the two proteins 
at levels comparable to the LI-MVI 
(Figure 2b and 2d). To confirm the 
specificity of this observation, we also 
assessed the effect of transiently over-
expressing two mutants of the NI 
isoform, each carrying mutations that 
abolish one of the two binding motifs 
(Figure 2c and 2d). As expected, the 
GFP-NI-MVI (WWY/WLY), in which the 
WWY binding site is abolished, did not 
show any colocalization with DAB2. In 
contrast, mutation of the RRL motif did 
not affect the colocalization with DAB2. 
In fact, there was a slight increase in 
colocalization, which may relate to an 
increase in free MVI available to 
interact with WWY binding partners. 
Overall, these observations are 
consistent with the conclusions from 
the titration measurements which 
suggest that significant interactions 
between the NI MVITAIL and tDAB2 can 
occur at higher protein concentrations. 
Therefore, our data support that the 
WWY binding site has a weaker affinity 
for protein-protein interactions. 
 
 
DAB2 mediates Myosin VI Large 
Insert isoform dimerization 
We have previously revealed how 
NDP52 interacts with MVI NI to bring 
about its unfolding (3). Unfolding 
subsequently exposes dimerization 
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sites, leading to protein oligomerization. 
However, the ability of the LI isoform to 
dimerise has not been yet explored. 
The presence of the additional alpha 
helix in this isoform may perturb its 
dimerization. To test if DAB2 can 
oligomerize both isoforms, we 
performed a FRET assay, whereby two 
pools of MVITAIL(NI) or MVITAIL(LI) were 
labelled, one with FITC and the other 
one with Alexa555. Titrations revealed 
a weak association between the two tail 
pools (Figures 3a and 3b), consistent 
with our previous results (3). Upon 
addition of 20 PM excess tDAB2, a 
change in FRET signal was observed, 
indicating the formation of a dimer 
complex. This occurred with both the NI 
and LI tails, with the LI signal being 
higher possibly due the higher 
association with tDAB2. 20 PM excess 
of NDP52 was able to trigger 
dimerization of MVITAIL(NI) but failed to 
significantly dimerize the MVITAIL(LI), 
consistent with the poor binding of 
NDP52 to the LI isoform.  
Taking all our data together, we 
propose the following model: NDP52 
specifically associates with MVI-NI 
through the RRL motif to trigger 
unfolding of the protein and subsequent 
dimerization. Similarly, binding of DAB2 
to the LI isoform through the WWY motif 
also leads to dimerisation. Whilst DAB2 
has also the ability to bind the NI 
isoform, its weaker affinity for the WWY 
motif makes this interaction less 
favourable compared to the high affinity 
binding of NDP52 to the RRL motif. In 
this way, the unfolding and dimerization 
of the NI isoform is preferentially 
assigned to the RRL binding partners.   
 
Effect of binding partner competition 
upon the biochemical properties of 
nuclear myosin VI 
We have shown that association of a 
binding partner with either the RRL or 
the WWY motif can bring about 
dimerization. We have also shown that 
the selectivity of MVI for its binding 
partners is regulated by the differential 
affinity between the two motifs. 
However, what is the biological impact 
of this binding partner selectivity and 
what would be the effect if its gets 
disrupted? More specifically, what is 
the effect of DAB2 upon the function of 
nuclear MVI, which we previously 
identified as the NI isoform? We have 
established that DAB2 can interact with 
this isoform at high protein 
concentrations. Interestingly, DAB2 can 
also be detected in the nucleus (Figure 
4a) and therefore it could interact with 
nuclear MVI.  
We have previously shown that MVI 
contains a DNA binding site on two 
conserved loops in the CBD 
(Supplementary Figure 1a) (3). These 
sites are only exposed upon unfolding 
of the tail domain and therefore, DNA 
binding is dependent upon the 
interaction with a binding partner (3). 
First, we wanted to assess the effect of 
binding partners upon the ability of MVI 
to bind DNA, which is critical for its role 
in transcription (3). To determine DNA 
binding, we measured the fluorescence 
anisotropy of labelled DNA. As reported 
previously (3), NDP52 independently 
binds to DNA itself and therefore, it is 
unsuitable for this purpose. In contrast, 
tDAB2 does not bind DNA 
(Supplementary Figure 1b) and 
therefore it can be used to determine its 
impact upon MVI binding DNA. To this 
end, we monitored the binding of MVI 
CBD to fluorescently labelled DNA 
(Figure 4b). Whereas the CBD alone 
could bind to DNA with strong affinity 
(Kd 140 nM), the presence of DAB2 
inhibited DNA binding in a 
concentration-dependent manner. 
Interestingly, the DNA binding sites of 
MVI are in close proximity to the WWY 
motif where DAB2 binds 
(Supplementary Figure 1a). Therefore, 
the interaction of DAB2 with MVI might 
induce a steric hindrance, or a 
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structural change within the CBD, 
which prevents the complex from 
binding DNA.  
 The ability of MVI to bind DNA is 
important for efficient in vitro 
transcription (Fili et al). Therefore, to 
assess the effect of DAB2 on the 
transcription activity of MVI, we 
performed in vitro transcription assays 
using the HeLaScribe nuclear extracts 
(Figure 4c). Antibody-depletion of MVI 
leads to a 70 % decrease in 
transcription yield. A similar impact is 
achieved through the addition of 
recombinant CBD to displace MVI. 
Interestingly, addition of 10 PM 
recombinant tDAB2 leads to a 60 % 
decrease in transcription. We therefore 
propose that this effect is due to tDAB2 
interfering with the DNA binding ability 
of MVI in the HeLaScribe lysate. This 
effect was observed in a concentration-
dependent manner, consistent with our 
anisotropy data. The addition of 10 PM 
NDP52 did not decrease the 
transcription yield suggesting that the 
tDAB2 effect is not due to sequestering 
MVI through binding to the protein. 
Moreover, no further decrease in 
transcription yield was found when 
tDAB2 was added following antibody-
depleted of MVI.  
The compromised transcription activity 
that we observed following antibody-
depletion of MVI can be partially 
rescued through the addition of 
recombinant MVI (Figure 4d). Addition 
of recombinant MVI and NDP52 
together can restore transcription to 
about 60% (Figure 4d), possibly due to 
the unfolding and dimerization of the 
protein. However, addition of 
recombinant MVI and tDAB2 together 
failed to rescue the transcription yield, 
reinforcing that the observed effect is 
specific to DAB2, possibly through its 
interference with DNA binding. Taken 
together, our data suggest that DAB2 is 
a negative regulator of the transcription 
activity of MVI.  
 
Effect of binding partner competition 
upon the nuclear functions of 
myosin VI 
We have shown how two different 
binding partners can have contrasting 
effects on the biochemical properties 
and activity of MVI in vitro. On this 
basis, we then wanted to explore the 
impact of different binding partners on 
the cellular function of MVI, and in 
particular its nuclear role in breast 
cancer cell line MCF-7. MVI is also 
distributed throughout the cell body, 
including the nucleus (Figure 5a). In 
these cells, MVI has been already 
shown to be required for the expression 
of genes responsive to estrogen 
receptor (ER) signalling. When MCF-7 
cells underwent siRNA knockdown of 
MVI, or treatment with TIP, the small 
molecule inhibitor of MVI, there was a 
decrease in the expression of estrogen-
activated PS2 and GREB1 (Figure 5b). 
The impact of both treatments was 
similar, with a decrease of 70-80% for 
PS2 and 30-40% for GREB1. Inhibition 
of MVI with TIP has already been 
shown to decrease the transcription 
yield in vitro (20). Based on our data, 
we can now suggest the motor activity 
of MVI is required for ER signalling. 
The genes that are under the control of 
the estrogen receptor relate, amongst 
others, to cell growth. Given the role of 
MVI in the expression of these genes, 
we then assessed the effect of MVI 
knockdown on MCF-7 growth (Figure 
5c). Indeed, the loss of MVI attenuates 
cell growth, which suggests there is a 
correlation between the role in gene 
expression and overall cell growth. 
MCF-7 cells, along with many other 
estrogen receptor positive breast and 
ovarian cancer cell lines, have lost or 
attenuated DAB2 expression 
(Supplementary Figure 2a). Moreover, 
the reintroduction of DAB2 to these cell 
lines has been suggested to suppress 
tumourgenicity (17).  Based upon the 
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impact of MVI on the ER driven gene 
expression and our in vitro data 
demonstrating the impact of DAB2 
upon MVI associated transcription, we 
wished to explore whether 
reintroduction of DAB2 in MCF-7 could 
lead to a perturbation of in the 
expression of ER target genes. To this 
end, we transiently expressed full 
length DAB2-mRFP in MCF-7 cells 
(Supplementary Figure 2a and b) and 
then monitored the expression of PS2 
and GREB1. Interestingly, the 
presence of DAB2 in MCF-7 resulted in 
a 20-30% decrease in the expression of 
these ER-target genes. 
To confirm that this decrease is due to 
the targeting of MVI, we transiently 
expressed in MCF-7 two truncations of 
DAB2 (Supplementary Figure 2c): the 
DAB2649-770 region which contains the 
MVI binding site and is the one used in 
our biochemical assays, and the 
DAB21-648 which cannot associate with 
MVI (12). As expected, the DAB2649-770 
resulted in a 40-50% decrease in the 
expression of the two ER target genes, 
whereas the DAB21-648 did not have any 
effect, confirming that the observed 
decrease in gene expression is indeed 
due to the interaction of DAB2 with MVI. 
Overall, our observations suggest that 
DAB2 can function in the cell as a 
negative regulator of MVI in the 
expression of ER-target genes. 
 
DISCUSSION 
The structural regulation of MVI 
controls its biochemical properties and 
therefore directly impacts on the 
cellular function of this motor protein. 
Here, we have explored what is the 
impact of binding partners on the 
conformation of MVI, how these 
interactions are regulated and how this 
regulation varies between isoforms. We 
have then investigated how the 
selectivity of MVI for its binding partner 
can affect its biochemical properties 
and intracellular functions.   
The structural regulation of MVI seems 
to follow a single general mechanism, 
which is summarised by the following 
model: MVI exists as a folded monomer 
which interacts with binding partners 
through the CBD. These interactions 
lead to MVI unfolding, and subsequent 
dimerization of the protein through its 
tail domain. As shown previously, this 
generates a processive motor protein 
(3).  
Moreover, here we have shown that 
this widely applied mechanism of 
structural regulation is under the control 
of a finely tuned interplay between 
binding partners and the MVI isoforms. 
In the case of the LI isoform, structural 
studies have revealed how the RRL 
motif is blocked by the LI helix (18), 
allowing only the WWY partners, such 
as DAB2, to bind to MVI. We have 
confirmed this here biochemically, by 
measuring the binding partner 
interactions at each site, using DAB2 as 
a representative example. In contrast, 
the NI isoform, in which both the RRL 
and WWY motif are readily accessible, 
should be able associate with any 
partner. We have therefore explored 
the mechanism underlying the partner 
selectivity in this case. We have 
revealed that the NI isoform can enact 
selectivity through the differential 
affinity between the two sites, with the 
RRL motif having stronger binding 
affinity over the WWY. In this way, the 
selectivity for binding partners is based 
upon the relative concentration of WWY 
versus RRL partners. While the overall 
cellular concentrations of DAB2 is 
unlikely to be in the micromolar range. 
However, it is possible for there to be 
local high protein concentrations which 
can generate micromolar 
concentrations within a defined volume. 
In these instances interactions between 
MVI and binding partners would be 
observed. Moreover, cellular 
interactions may be supported by 
additional protein/cargo factors thereby 
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increasing the affinity. There could also 
be a global change in protein 
expression levels. For instance, the 
loss of a WWY partner would perturb 
the dynamics leading to an enhanced 
role of RRL binding partners.  
 This mechanism of selectivity is 
particularly relevant for the regulation of 
nuclear MVI, which is the NI isoform (3). 
Here, we have demonstrated the 
impact of a concentration driven 
interaction with the low affinity binding 
partner DAB2. Indeed, interaction with 
DAB2 blocked the ability of MVI to bind 
DNA and subsequently its transcription 
activity in vitro. 
The impact of DAB2 of the biochemical 
properties of MVI raised questions 
about its impact on the cellular 
functions of MVI. DAB2 has been 
proposed to function as a tumour 
suppressor however, the underlying 
mechanism remains elusive. Here, we 
have proposed that at least part of this 
activity could relate to the down-
regulation of nuclear MVI in 
transcription. As nuclear MVI is linked 
to estrogen receptor gene expression, 
this would in turn attenuate the activity 
of the estrogen receptor, subsequently 
leading to a decrease in tumorgenicity. 
Conversely, loss of a DAB2 would 
perturb the dynamics leading to an 
enhanced role of RRL binding partners, 
like NDP52 leading to enhanced MVI 
transcription activity. Cancer cell lines, 
such as the MCF-7, over-express the 
NI isoform of MVI, which is the one able 
to translocate to the nucleus, and they 
are therefore primed for transcriptional 
activity. This is further enhanced in 
MCF-7 cells by the loss of DAB2 
expression, which relieves the DAB2-
mediated negative regulation. Overall, 
this would lead to a high level of ER 
activity, which is MVI-dependent. 
Interestingly, reintroduction of DAB2 in 
these cells has an effect on their 
tumorigenic potential (17). In this study, 
we have confirmed that reintroduction 
of DAB2 perturbs the transcription 
landscape downstream the ER and 
revealed this is due to MVI targeting. 
We therefore suggest that the down-
regulation of the transcriptional activity 
of MVI is indeed part of the role of DAB2 
as a tumour suppressor. 
In summary, this study has allowed us 
to gain new insights into the regulation 
of MVI. The mechanism of selectivity of 
binding partners is isoform depended. 
While the LI MVI employs a structural 
selection for its binding partners, the 
selectivity of the NI isoform is regulated 
by the relative expression levels of the 
partners. Finally, we provide an 
example of how the intracellular levels 
of MVI binding partners can modulate 
the cellular function of the protein. We 
propose that the tumour suppressor 
activity of DAB2 is, in part, related to the 
down-regulation of estrogen receptor 
target gene activation by nuclear MVI. 
These insights open new avenues for 
exploring how the activity of this multi-
functional motor protein is regulated 
within the nucleus and the cytoplasm, 
as well.  
 
 
 
 
 
METHODS 
Constructs 
A list of constructs and PCR primers are 
provided in Supplementary Table 1 and 
2, respectively. Constructs generated in 
this work are described below: The 
following human full-length Myosin VI 
mutants (EGFP-C3-NI-MVI-RRL-AAA 
and EGFP-C3-NI-MVI-WWY-WLY) 
were a kind gift from F. Buss (CIMR). 
The full length human DAB2-mRFP 
was isolated by PCR from pET28a-
DAB2-RFP plasmid, restriction 
digested with NheI and NotI and cloned 
into the pZsgreen1-N1 backbone 
following removal of Zsgreen1. The 
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human DAB2 truncations were 
generated by PCR isolation of the 
DAB2 fragment containing the Myosin 
VI binding site (aa 649-770) and the 
rest of DAB2 (aa 1-648) which does not 
contain the Myosin VI binding site from 
the above DAB2-mRFP plasmid. The 
PCRs were restriction digested by XhoI 
and SacII and cloned into pEGFP-C3. 
 
Protein expression and purification 
in Escherichia coli 
Recombinant constructs were 
expressed in E.coli BL21 DE3 cells 
(Invitrogen) in Luria Bertani media. 
Proteins were purified by affinity 
chromatography (HisTrap FF, GE 
Healthcare). The purest fractions were 
further purified through a Superdex 200 
16/600 column (GE Healthcare).  
 
Protein Expression using 
Baculovirus system 
Full-length myosin VI NI and LI and 
Xenopus calmodulin were expressed in 
Sf9 and Sf21 (Spodoptera frugiperda) 
insect cells using the Baculovirus 
expression system. Sf9 cells were 
cultured in suspension in sf900 media 
(Gibco) at 27ºC to generate the P1-3 
recombinant baculovirus stocks. 
Finally, expression of recombinant 
proteins was set up by infecting sf21 
cells with the P3 viral stock in ExCell 
420 media (Sigma). The cells were 
harvested by centrifugation (as above) 
for protein purification after 4 days. 
Prior to sonication, an additional 5 mg 
Calmodulin was added with 2 mM DTT. 
After sonication, 5 mM ATP and 10 mM 
MgCl2 were added and the solution was 
rotated at 4 °C for 30 min before 
centrifugation (20,000g, 4°C, 30 min). 
Then, the cell lysate was subjected to 
the purification steps described above. 
 
Protein labelling 
Proteins were transferred into 50 mM 
Na-phosphate (pH 6.5) using a PD10 
desalting column. Samples were then 
incubated with a 5-fold excess of dye 
for 4 hours, rotating at 4°C . Excess dye 
was removed using a PD10 desalting 
column pre-equilibrated with 50 mM 
Na-Phosphate, 150 mM NaCl and 1 
mM DTT. Labelling efficiency was 
calculated based on the absorbance at 
280 nm and the absorbance maximum 
of the dye. Typical efficiency was 90%, 
whereby the less than complete 
labelling was taken as an indicator for a 
single dye per protein. This was tested 
for isolated preparations in mass 
spectroscopy, which revealed both an 
unlabelled and single labelled 
population. 
 
Cell culture and Transfection 
HeLa (ECACC 93021013) and MCF7 
(ECACC 86012803) cells were cultured 
at 37ºC and 5% CO2, in Gibco MEM 
Alpha medium with GlutaMAX (no 
nucleosides), supplemented with 10% 
Fetal Bovine Serum (Gibco), 100 
units/ml penicillin and 100 µg/ml 
streptomycin (Gibco). For the transient 
expression of MVI isoforms and 
mutants, full length DAB2 and 
truncations, HeLa cells and/or MCF7 
cells grown on glass coverslips were 
transfected with EGFP-NI-MVI, EGFP-
LI-MVI, EGFP-NI-MVI-RRL-AAA, 
EGFP-NI-MVI-WWY-WLY, DAB2-
mRFP, EGFP-DAB2-1-648 and EGFP-
DAB2-649-770 constructs using 
Lipofectamine 2000 (Invitrogen), 
IROORZLQJ WKH PDQXIDFWXUHU¶V
instructions. Depending on the 
construct, 24 h - 72 h after transfection, 
cells were subjected to nuclear staining 
using Hoechst 33342 (Thermo 
Scientific), fixed and analysed or 
subjected to indirect 
immunofluorescence (see below).  
Full length DAB2-RFP cDNA was 
electroporated into MCF7 cells using 
BioRad Gene Pulser Xcell TM 
electroporation system. After 
trypsinization, harvested cells were 
washed with 1X PBS, counted and 
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1.5x106 cells were resuspended in 
800ul of cold Opti-MEM media and the 
cell suspension was kept on ice. 10ug 
of DNA was added to the cell 
suspension and the mixture was 
transferred to the Biorad 4mm cuvette. 
The cells were then pulsed using 
exponential-decay protocol with a 
voltage of 300V and a capacitance of 
350µF. Cells were allowed to recover 
for 5 minutes after which warm 
complete media (MEM) was added to 
them and they were plated in a 6 well 
plate at a density of 0.5x106 cells per 
well. The cells were collected for 
protein or RNA extraction after 48 
hours. 
 
Immunofluorescence  
Transfected and non-transfected HeLa 
or MCF-7 cells were fixed for 15 min at 
room temperature in 4% (w/v) 
paraformaldehyde (PFA) and residual 
PFA was quenched for 15 min with 50 
mM ammonium chloride. All 
subsequent steps were performed at 
room temperature.  Cells were 
permeabilised and simultaneously 
blocked for 15 min with 0.1 % (v/v) 
Triton X-100 and 2 % (w/v) BSA in PBS. 
Cells were then immuno-stained 
against the endogenous proteins by 1 
hour incubation with the indicated 
primary and subsequently the 
appropriate fluorophore-conjugated 
secondary antibody (details below), 
both diluted in 2% (w/v) BSA in PBS. 
The following antibodies were used at 
the indicated dilutions: Rabbit anti-MVI 
(1:200, Atlas-Sigma HPA0354863-
100UL), Mouse anti-DAB2 (1:100, 
Abcam ab88590) ,donkey anti-mouse 
Alexa Fluor 488-conjugated (1:500, 
Abcam Ab181289), donkey anti-mouse 
Alexa Fluor 555-conjugated (1:500, 
Abcam Ab150110), donkey anti-rabbit 
Alexa Fluor 488-conjugated antibody 
(1:500, Abcam Ab181346) and donkey 
anti-rabbit Alexa Fluor 555-conjugated 
antibody (1:500, Abcam Ab150074). 
Coverslips were mounted on 
microscope slides with Mowiol (10% 
(w/v) Mowiol 4-88, 25% (w/v) glycerol, 
0.2 M Tris-HCl, pH 8.5), supplemented 
with 2.5% (w/v) of the anti-fading 
reagent DABCO (Sigma).  
For co-localisation analysis, 20 
Fields of view were recorded with 2-4 
cells per field. We ensured all cells were 
transfected within the field. Pearson's 
coefficients were obtained with the 
JACoP plugin(21) for ImageJ. 
 
Immunoblot Analysis 
The total protein concentration was 
determined by Bradford Assay (Sigma) 
IROORZLQJ WKH PDQXIDFWXUHU¶V
instructions. Cell lysates were heat-
denatured and resolved by SDS-PAGE. 
The membrane was probed against the 
endogenous proteins by incubation with 
mouse Anti-DAB2 polyclonal antibody 
(1:1000, Abcam ab88590) and 
subsequently a goat anti-mouse 
antibody coupled to horseradish 
peroxidase (1:15000, Abcamab97023). 
The bands were visualised using the 
ECL Western Blotting Detection 
Reagents (Invitrogen) and the images 
were taken using Syngene GBox 
system. Images were processed in 
ImageJ. 
 
Fluorescence Imaging 
Cells were visualised using either the 
ZEISS LSM 880 confocal microscope 
or the widefield Olympus IX71 
microscope. The former was equipped 
with a Plan-Apochromat 63x 1.4 NA oil 
immersion lens (Carl Zeiss, 420782-
9900-000). Three laser lines, i.e. 405 
nm, 488 nm and 561 nm, were used to 
excite the fluorophores, i.e. Hoechst, 
GFP and RFP, respectively. The built-
in dichroic mirrors (Carl Zeiss, MBS-
405, MBS-488 and MBS-561) were 
used to reflect the excitation laser 
beams on to cell samples. The 
emission spectral bands for 
fluorescence collection were 410 nm-
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524 nm (Hoechst), 493 nm-578 nm 
(GFP) and 564 nm-697 nm (RFP). The 
detectors consisted of two multi anode 
photomultiplier tubes (MA-PMT) and 1 
gallium arsenide phosphide (GaAsP) 
detector. The green channel (GFP) was 
imaged using GaAsP detector, while 
the blue (Hoechst) and red (RFP) 
channels were imaged using MA-
PMTs. ZEN software (Carl Zeiss, ZEN 
2.3) was used to acquire and render the 
confocal images. The later was 
equipped with an PlanApo 
100xOTIRFM-SP 1.49 NA lens 
mounted on a PIFOC z-axis focus drive 
(Physik Instrumente, Karlsruhe, 
Germany), and illuminated with an 
automated 300W Xenon light source 
(Sutter, Novato, CA) with appropriate 
filters (Chroma, Bellows Falls, VT). 
Images were acquired using a 
QuantEM (Photometrics) EMCCD 
camera, controlled by the Metamorph 
software (Molecular Devices). The 
whole volume of cells was imaged by 
acquiring images at z-steps of 200 nm. 
Widefield images were deconvolved 
with the Huygens Essential version 
17.10 software. Confocal Images were 
deconvolved using the Zeiss Zen2.3 
Blue software, using the regularised 
inverse filter method. All images were 
then analysed by ImageJ.  
 
Incucyte  
Cells were seeded onto 96-well tissue 
culture dishes at equal densities in 6 
replicates. After attachment over-night, 
cells were transfected with MVI siRNA. 
Photomicrographs were taken every 
hour using an IncuCyte live cell imager 
(Essen Biosciences, Ann Harbor, MI) 
and confluency of cultures was 
measured using IncuCyte software. 
Confluency values between wells were 
normalised to initial confluency for 
comparison. 
 
RNA extraction and RT-qPCR 
RNA from DAB2-RFP transfected or 
non-transfected MCF7 cells was 
extracted using Gene Jet RNA 
purification kit (Thermo scientific) 
DFFRUGLQJ WR PDQXIDFWXUHU¶V SURWRFRO
The RNA concentration was measured 
using Geneflow Nanophotometer and 
RT-qPCR was performed with one-step 
QuantiFast SYBR Green qPCR kit 
(Qiagen) using 50ng of RNA in each 
sample. A list of qPCR primers is given 
in Supplementary Table 3. 
 
DNA Substrates 
DNA substrate ds40 consisted of 
Labeled 
(TTAGTTGTTCGTAGTGCTCGTCTG
GCTCTGGATTACCCGC*FAM) 
and unlabelled 
(GCGGGTAATCCAGAGCCAGACGA
GCACTACGAACAACTAA) 
 oligonucleotides purchased from IDT. 
To form duplex DNA substrates, 
oligonucleotides were mixed at 
equimolar concentrations at either 50 
ȝ0 LQ ZDWHU RU D EXIIHU FRQWDLQLQJ 
mM Tris.HCl at pH 7.5, 150 mM NaCl, 
and 3 mM MgCl2.  
 
In vitro transcription  
The DNA template was the pEGFP-C3 
linearized plasmid containing the CMV 
promoter which would generate a 130-
base run-off transcript. The HelaScribe 
(Promega) reactions were performed in 
triplicates, through two independent 
experiments, according to the 
PDQXIDFWXUHU¶V LQstructions. The 
reactions were performed for 60 min at 
25°C.  
Reactions were also performed 
following pre-clearance with the MVI 
antibody. Protein G Dynabeads 
(Invitrogen) were prepared according to 
PDQXIDFWXUHU¶V LQVWUXFWLRQV EHIRUH
being loaded with 4 Pg antibody. 
Samples were incubated for 30 min on 
ice and beads were extracted 
immediately before performing the 
transcription reaction. 
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For quantification, mRNA was purified 
using Gene Jet RNA purification kit 
(Thermo scientific) according to 
PDQXIDFWXUHU¶V protocol and RT-qPCR 
was performed with one-step 
QuantiFast SYBR Green qPCR kit 
(Qiagen).  
 
 
Titration measurements  
All reactions were performed at 25 qC in 
a buffer containing 50 mM TrisHCl (pH 
7.5), 150 mM sodium chloride and 1 
mM DTT in a final volume of 100 PL.  
Measurements were performed using a 
ClarioStar Plate Reader (BMG 
Labtech).  
Intensity measurements were 
performed at the following 
wavelengths: FITC (ex. 490nm), Alexa 
Fluor 555 (ex. 555nm). FITC to Alexa 
Fluor 555 FRET measurements were 
performed using the following 
wavelengths ex. 470nm and em. 
575nm. Anisotropy was measured with 
the instrument in the T format, allowing 
simultaneous acquisition of parallel (I//) 
and perpendicular (Iŏ) components 
using BMG filter-sets for fluorescein 
(Ex. 482/16-10, Dichroic LP504 and 
em. 530/-40). 
 
Analysis of kinetic data  
For Fluorescence Anisotropy titrations: 
Anisotropy was calculated, as 
described below, based upon 
established procedures (22),(23-25). 
Total fluorescence intensity (Ft) is given 
by: ܨ௧ ൌ ෍ ܿ௜ܨ௜ 
Total anisotropy (At) is given by: ܣ௧ ൌ  ?ܿ௜ܨ௜ܣ௜ܨ௧  
 
Where ci is the concentration of species 
i, Fi is the fluorescence intensity per unit 
of concentration and Ai is the 
anisotropy. This is calculated from the 
parallel and perpendicular fluorescence 
intensity (I) in relation to the plane of 
excitation by: ܣ௜ ൌ  ܫ௣௔௥௔௟௟௘௟ െ ܫ௣௘௥௣௘௡ௗ௜௖௨௟௔௥ܫ௣௔௥௔௟௟௘௟ ൅  ?ܫ௣௘௥௣௘௡ௗ௜௖௨௟௔௥ 
As anisotropy is additive for multiple 
fluorescence species in solution, it is 
used to give a measure of their relative 
concentrations. For MVI (and various 
constructs) there are two fluorescence 
species, DNA and MVI.DNA. The total 
anisotropy can then be calculated in 
terms of the dissociation constant (Kd) 
for the MVI.DNA complex: ܣ௧ ൌ஺ವಿಲሺሾ஽ே஺ሿ೟ିሾெ௏ூǤ஽ே஺ሿሻା஺ಾೇ಺Ǥವಿಲொሾெ௏ூǤ஽ே஺ሿሾ஽ே஺ሿ೟ିሾெ௏ூǤ஽ே஺ሿାொሾெ௏ூǤ஽ே஺ሿ   
Where  ሾܯܸܫǤ ܦܰܣሿ ൌሺሾெ௏ூሿ೟ାሾ஽ே஺ሿ೟ା௄೏ሻିඥሺሾெ௏ூሿ೟ାሾ஽ே஺ሿ೟ା௄೏ሻమିସሾெ௏ூሿ೟ሾ஽ே஺ሿ೟ଶ   
And where [MVI]t and [DNA]t are the 
total concentrations for each reactant. 
[MVI.DNA] is the concentration of the 
protein-bound DNA complex. Q is the 
fluorescence intensity of MVI.DNA 
relative to DNA. The anisotropy data 
were fitted to obtain dissociation 
constants based on the above 
equations using GraFit fitting software 
(Leatherbarrow, R. J. (2001) Grafit 
Version 5, Erithacus Software Ltd., 
Horley, U.K.). 
 For the FRET titrations: The 575 
nm intensity data was corrected for the 
increase in intensity due to a small 
direct excitation. This background 
signal was subtracted from the dataset 
to leave the FRET values. The titration 
curves for the MVITAIL interactions were 
fitting to a binding quadratic equation: 
 ሾܥ݋݉݌݈݁ݔሿൌ  ሺሾܨܫܶܥሿ௧ ൅ ሾܣܨ ? ? ?ሿ௧ ൅ ܭௗሻ െ ඥሺሾܨܫܶܥሿ௧ ൅ ሾܣܨ ? ? ?ሿ௧ ൅ ܭௗሻଶ െ  ?ሾܨܫܶܥሿ௧ሾܣܨ ? ? ?ሿ௧ ?  
 
Data Availability 
The data supporting the findings of this 
study are available from the 
corresponding author on request. 
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FIGURES 
 
Figure 1 Interaction between Myosin VI and binding partners NDP52 and DAB2. 
(a) Cartoon depiction of the key regions of the MVITAIL, as discussed in the text. This 
highlights position of the large insert, along with NDP52 and DAB2 binding sites. 
(b) Cartoon depiction of MVI backfolding with contacts between the CBD and motor, 
as described in (3). 
(c) FRET titration of MVITAIL(NI) against 1 PM NDP52 (red triangles) or tDAB2 (blue 
squares). 
 
(d) FRET titration of MVITAIL(LI) against 1 PM NDP52 (red triangles) or tDAB2 (blue 
squares).  
All titration data fitting was performed as described in Methods giving a Kd as plotted 
(Error bars represent SEM from three independent experiments). 
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Figure 2 Myosin VI interaction with DAB2 in HeLa cells. 
(a) Immunofluorescence staining against MVI (green) and DAB2 (magenta) in HeLa 
cells. White foci depict colocalization. 
(b) Representative images of transiently expressed NI- and LI-GFP-MVI in HeLa cells 
combined with immunofluorescence staining against DAB2.  
(c) Representative images of transiently expressed NI-MVI mutants WWY/WLY and 
RRL/AAA in HeLa cells combined with immunofluorescence staining against DAB2. 
Scale bar 10 Pm in all images. 
(d) 3HDUVRQ¶VFRHIILFLHQWIRUMVI colocalisation with DAB2 from images in a-c. Figure 
was generated using (26). Each data point represents a field of view consisting of 2-4 
cells. *** represents a p<0.001 by two-tailed t-test. 
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Figure 3 Binding partner driven dimerization of myosin VI. 
 (a) FRET titration of AF555-MVITAIL(NI) against 1 PM FITC-MVITAIL(NI) +/- tDAB2 (20 
PM) and NDP52 (20 PM). Data fitting generated NDP52 KdDIMER as 4.3 PM and tDAB2 
KdDIMER as 5.3 PM 
(b) FRET titration of AF555-MVITAIL(LI) against 1 PM FITC-MVITAIL(LI) +/- tDAB2 (20 PM) 
and NDP52 (20 PM). Data fitting generated
 
NDP52 KdDIMER as 9.3 PM and tDAB2 
KdDIMER as 3.3 PM. 
All titration data fitting was performed as described in Methods (Error bars represent 
SEM from three independent experiments). 
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Figure 4 DAB2 represses the in vitro activity of nuclear myosin VI. 
(a) Immunofluorescence staining against DAB2 (magenta) combined with DNA 
staining (Cyan) in HeLa cells. Scale bar 10 Pm in all images. 
(b) Fluorescence anisotropy titrations of the CBD against a 40 bp fluorescein amidite 
(FAM)-DNA (50 nM) with the highlighted concentrations of tDAB2. Data fitting was 
performed as described in Methods (Kd +/- SEM n = 3 independent experiments).  
(c) In vitro transcription by HelaScribe extracts following antibody depletion as 
described in Methods, or in the presence of CBD at 25 PM, tDAB2 at 1 or 10 PM and 
NDP52 at 10 PM. Samples were normalized to a non-depleted control reaction. *** 
represents a p<0.001 by two-tailed t-test. (d) In vitro transcription following antibody 
depletion and rescue using recombinant MVI (NI) (1 PM), NDP52 (10 PM) or tDAB2 
(10 PM), as described in Methods *** represents a p<0.001 by two-tailed t-test. 
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Figure 5 Inhibition of myosin VI in estrogen linked gene expression. 
(a) Immunofluorescence staining against MVI (magenta) combined with DNA staining 
(Cyan) in HeLa cells. Scale bar 10 Pm in all images. 
(b) Expression of estrogen receptor gene targets following siRNA knockdown of MVI 
(red), or TIP treatment (blue) in MCF-7 cells. Expression is plotted as a percentage of 
expression in mock cells. MYO6 reports on the success of the siRNA knockdown, 
whilst ESR1 and ACTB were used to reflect global changes in transcription. *** 
represents a p<0.001 by two-tailed t-test. 
(c) Real-time growth of MCF-7 cells (red) and corresponding measurements following 
MVI siRNA knockdown (green) and mock transfection control (blue). Data represent 
three independent measurements and error bars show SEM. Example images at start 
and end time points are shown. Scale bar 300 Pm in all images. Western-blot against 
DAB2 following transient transfection in to MCF-7 cells is shown in Supplementary 
Figure 2A. 
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(d) Expression of estrogen receptor target genes following transient transfections of 
DAB2 (magenta), DAB21-648 (blue) and DAB2649-770 (red) in to MCF-7 cells. Expression 
is plotted as a percentage of expression in non-transfected cells. MYO6, ESR1 and 
ACTB were used to reflect global changes in transcription. (Error bars represent SEM 
from 3 independent experiments. *** represents a p<0.001 by two-tailed t-test.). 
 
 
 
 
 
 
 
 
 
 
 
